SciSparc Ltd

NASDAQ:SPRC

1.23

-0.06 (-4.65%)

7:59:49 PM EDT: $1.24 +0.01 (+0.81%)

SciSparc Ltd Stock, NASDAQ:SPRC

20 Raul Wallenberg Street`, Tower A, Tel Aviv, Tel Aviv 6971916

Israel

Phone: +972.3.717.5777

Number of Employees: 4

http://www.scisparc.com

Description

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.